EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Epinephrine Challenge

Benjamin M Moore, Christian Steinberg, Rafik Tadros, Julia Cadrin-Tourigny, Douglas Chan, Brianna Davies, Zachary W M Laksman, Jason D Roberts, Shubhayan Sanatani, Ciorsti MacIntyre, David Lee, Martin S Green und 12 weitere

JACC: Clinical Electrophysiology · 2026

DOI: 10.1016/j.jacep.2026.03.033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Clinical Electrophysiology, 2026. Verfasst von Benjamin M Moore und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Epinephrine, Death, Sudden, Cardiac, Long QT Syndrome, Tachycardia, Ventricular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The diagnostic implications of a positive epinephrine challenge for long QT syndrome (LQTS) or catecholaminergic polymorphic ventricular tachycardia (CPVT) are not well understood. Test interpretation is challenging, and false positives may be substantial. OBJECTIVES: This study sought to assess the test performance of epinephrine challenge for the diagnosis of LQTS and CPVT, utilizing long-term follow up. METHODS: The sensitivity, specificity, positive likelihood ratio (LR+), and negative likelihood ratio (LR-) of epinephrine challenge for the diagnosis of LQTS and CPVT were assessed in consecutive patients from the Hearts in Rhythm Organization registry, comparing to final working diagnosis according to guideline-derived diagnostic criteria, incorporating repeat phenotyping, and informed by targeted genetic testing over long-term follow-up. RESULTS: A total of 376 consecutive patients undergoing epinephrine challenge were followed for a mean duration of 8.6 ± 5.3 years (250 patients with unexplained cardiac arrest [UCA] and 176 first-degree relatives). The sensitivity, specificity, LR+, and LR- of epinephrine for the diagnosis of LQTS, compared with final working diagnosis, were 90%, 79%, 4.4 (95% CI: 3.4-5.6), and 0.1 (95% CI: 0.0-0.4), respectively. QT prolongation with epinephrine demonstrated no significant correlation with end-recovery QTc on exercise stress testing. The sensitivity, specificity, LR+, and LR- of epinephrine for the diagnosis of CPVT, compared with final working diagnosis, were 62%, 93%, 8.9 (95% CI: 5.2-16.6), and 0.4 (95% CI: 0.2-0.8), respectively. A pathogenic LQTS variant was identified in only 15% of genotyped patients with a positive epinephrine challenge for LQTS, and a pathogenic CPVT variant in only 13% of patients with a positive epinephrine challenge for CPVT. Most patients with a positive epinephrine challenge for LQTS or CPVT had a "non-LQTS/CPVT" final working diagnosis (either UCA, unaffected, or an alternative Inherited arrhythmia syndrome). CONCLUSIONS: A positive epinephrine challenge demonstrated mild-moderate agreement with a final diagnosis of LQTS and CPVT. Most patients with an initial positive test result had their diagnosis revised to UCA, unaffected, or an alternative diagnosis over long-term follow-up. This study suggests that epinephrine challenge has limited utility as a "rule-in" test but may retain value in its negative predictive value for the UCA population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpinephrineDeath, Sudden, CardiacLong QT SyndromeTachycardia, VentricularHeart ArrestHumansFemaleMaleAdultSensitivity and SpecificityPolymorphic Catecholaminergic Ventricular TachycardiaMiddle AgedElectrocardiographyFollow-Up StudiesAdolescentYoung Adult

Stichwörter der Autor:innen

diagnosisepinephrine challengesudden cardiac deathunexplained cardiac arrest

Substanzen

Epinephrine

Autor:innen und Institutionen

  • Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Institut Universitaire de Cardiologie et Pneumologie de Quebec, Laval University, Quebec City, Quebec, Canada.
  • Cardiovascular Genetics Center, Montreal Heart Institute, Montreal, Quebec, Canada.
  • Population Health Research Institute, Hamilton, Ontario, Canada.
  • Children's Heart Centre, BC Children's Hospital, Vancouver, British Columbia, Canada.
  • Division of Cardiology, QEII Health Sciences Center, Halifax, Nova Scotia, Canada.

Förderung

  • Canadian Institutes of Health Research

Zitieren

APA

Moore, B. M., Steinberg, C., Tadros, R., Cadrin-Tourigny, J., Chan, D., Davies, B., Laksman, Z. W. M., Roberts, J. D., Sanatani, S., MacIntyre, C., Lee, D., Green, M. S., Khan, H. R., Roston, T. M., Makanjee, B., Ilhan, E., Hansom, S., Arbour, L., Seifer, C., …, & Krahn, A. D. (2026). Epinephrine Challenge. JACC: Clinical Electrophysiology. https://doi.org/10.1016/j.jacep.2026.03.033

Vancouver

Moore BM, Steinberg C, Tadros R, Cadrin-Tourigny J, Chan D, Davies B, et al. Epinephrine Challenge. JACC: Clinical Electrophysiology. 2026. doi:10.1016/j.jacep.2026.03.033

BibTeX
@article{Moore2026,
  author = {Moore, Benjamin M and Steinberg, Christian and Tadros, Rafik and Cadrin-Tourigny, Julia and Chan, Douglas and Davies, Brianna and Laksman, Zachary W M and Roberts, Jason D and Sanatani, Shubhayan and MacIntyre, Ciorsti and Lee, David and Green, Martin S and Khan, Habib R and Roston, Thomas M and Makanjee, Bhavanesh and Ilhan, Erkan and Hansom, Simon and Arbour, Laura and Seifer, Colette and Angaran, Paul and Simpson, Christopher S and Chauhan, Vijay S and Healey, Jeffrey S and Krahn, Andrew D},
  title = {Epinephrine Challenge},
  journal = {JACC: Clinical Electrophysiology},
  year = {2026},
  doi = {10.1016/j.jacep.2026.03.033}
}
Kostenlos starten →